Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

Objectives To report the impact of continued burosumab treatment on clinical laboratory tests of efficacy, patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia who continued from a 96-week phase 3 study into a 48-week open-label extension.Methods Eligibl...

Full description

Bibliographic Details
Main Authors: Karine Briot, Wei Sun, Rachel K Crowley, Maria Luisa Brandi, Stuart H Ralston, Peter Kamenický, Martine Cohen-Solal, Richard Keen, Angela Williams, Muhammad K Javaid, Robin H Lachmann, Annabel Nixon, Mark Nixon, Anne-Lise Lecoq, Sami Kolta, Jennifer S Walsh, Angela J Rylands
Format: Article
Language:English
Published: BMJ Publishing Group 2023-02-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/1/e002676.full

Internet

https://rmdopen.bmj.com/content/9/1/e002676.full

Similar Items